Photo by atikahakhtar from unsplash
Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α… Click to show full abstract
Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and certolizumab pegol), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab). Each class of biologics has distinct characteristics.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!